| Negative symptoms in schizophrenia: avolition and Occam's razor G Foussias, G Remington Schizophrenia bulletin 36 (2), 359-369, 2010 | 740 | 2010 |
| Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders G Foussias, O Agid, G Fervaha, G Remington European Neuropsychopharmacology 24 (5), 693-709, 2014 | 271 | 2014 |
| An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis O Agid, T Arenovich, G Sajeev, RB Zipursky, S Kapur, G Foussias, ... Journal of Clinical Psychiatry 72 (11), 1439, 2011 | 265 | 2011 |
| Motivational and neurocognitive deficits are central to the prediction of longitudinal functional outcome in schizophrenia G Fervaha, G Foussias, O Agid, G Remington Acta Psychiatrica Scandinavica 130 (4), 290-299, 2014 | 261 | 2014 |
| Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making G Fervaha, A Graff-Guerrero, KK Zakzanis, G Foussias, O Agid, ... Journal of psychiatric research 47 (11), 1590-1596, 2013 | 238 | 2013 |
| Impact of primary negative symptoms on functional outcomes in schizophrenia G Fervaha, G Foussias, O Agid, G Remington European Psychiatry 29 (7), 449-455, 2014 | 228 | 2014 |
| Treating negative symptoms in schizophrenia: an update G Remington, G Foussias, G Fervaha, O Agid, H Takeuchi, J Lee, M Hahn Current treatment options in psychiatry 3, 133-150, 2016 | 204 | 2016 |
| Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome G Fervaha, G Foussias, O Agid, G Remington Schizophrenia research 166 (1-3), 9-16, 2015 | 183 | 2015 |
| Neuroimaging evidence for the deficit subtype of schizophrenia AN Voineskos, G Foussias, J Lerch, D Felsky, G Remington, TK Rajji, ... JAMA psychiatry 70 (5), 472-480, 2013 | 179 | 2013 |
| Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits G Foussias, S Mann, KK Zakzanis, R Van Reekum, O Agid, G Remington Schizophrenia research 132 (1), 24-27, 2011 | 171 | 2011 |
| Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma A Moros, V Rodriguez, I Saborit-Villarroya, A Montraveta, P Balsas, ... Leukemia 28 (10), 2049, 2014 | 165* | 2014 |
| Does relapse contribute to treatment resistance? Antipsychotic response in first-vs. second-episode schizophrenia H Takeuchi, C Siu, G Remington, G Fervaha, RB Zipursky, G Foussias, ... Neuropsychopharmacology 44 (6), 1036-1042, 2019 | 159 | 2019 |
| Motivational deficits and cognitive test performance in schizophrenia G Fervaha, KK Zakzanis, G Foussias, A Graff-Guerrero, O Agid, ... JAMA psychiatry 71 (9), 1058-1065, 2014 | 156 | 2014 |
| Anhedonia in depression and schizophrenia: a transdiagnostic challenge C Lambert, S Da Silva, AK Ceniti, SJ Rizvi, G Foussias, SH Kennedy CNS neuroscience & therapeutics 24 (7), 615-623, 2018 | 135 | 2018 |
| Motivational deficits as the central link to functioning in schizophrenia: a pilot study G Foussias, S Mann, KK Zakzanis, R Van Reekum, G Remington Schizophrenia Research 115 (2-3), 333-337, 2009 | 134 | 2009 |
| Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls S Shahab, BH Mulsant, ML Levesque, N Calarco, A Nazeri, AL Wheeler, ... Neuropsychopharmacology 44 (5), 898-906, 2019 | 130 | 2019 |
| Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? G Remington, O Agid, G Foussias, L Ferguson, K McDonald, V Powell Psychopharmacology 225, 505-518, 2013 | 121 | 2013 |
| Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis AL Wheeler, M Wessa, PR Szeszko, G Foussias, MM Chakravarty, ... JAMA psychiatry 72 (5), 446-455, 2015 | 108 | 2015 |
| Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification S Farooq, O Agid, G Foussias, G Remington Schizophrenia bulletin 39 (6), 1169-1172, 2013 | 108 | 2013 |
| Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention O Agid, G Foussias, G Remington Expert Opinion on Pharmacotherapy 11 (14), 2301-2317, 2010 | 103 | 2010 |
